ANNX — Annexin Pharmaceuticals AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK55.46m
- SEK50.19m
Brief: Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln
Brief: Annexin Pharmaceuticals Gets International Nonproprietary Name Drug Candidate Anxv
Brief: Annexin Pharmaceuticals Updates On Nine Patients Treated In Nexus Study
Brief: Annexin's Rights Issue 98% Subscribed
Brief: Annexin Pharmaceuticals: ANXV Boosts Retinal Perfusion In RVO, DR Patients
Brief: Annexin Resolves Rights Issue Of About SEK 20 Mln
Brief: Annexin Receives German Approval For ANXV Clinical Trial
Brief: Annexin Secures Financing Through Bridge Loan Facility, Plans Rights Issue
Brief: Annexin Pharmaceuticals Q4 Net Loss At SEK 10.5 Mln
Brief: Annexin Gets Approval For Phase 2A Study In Diabetic Retinopathy, RVO
Brief: Annexin Q2 Loss Narrows To SEK 8.5 Mln
Brief: Annexin Pharmaceuticals Reports Q1 Loss Of SEK 8 Mln
Brief: Annexin Pharmaceuticals To Get SEK 50 Mln From Rights Issue
Brief: Annexin Pharmaceuticals Resolves On SEK 50 Million Rights Issue
Brief: Annexin Q3 Loss Widens To SEK 10.9 Mln
Brief: Annexin Reports Promising Topline Results In RVO Phase 2A Study
Brief: Annexin Pharmaceuticals Q2 Loss SEK 14.5 Mln
Brief: Annexin Resolves On Rights Issue Of SEK 45.1 Mln
Brief: Annexin Pharmaceuticals Q4 Loss Widens To SEK 14.5 Mln